Microba Life Valuation
| MAP Stock | 0.19 0.01 5.56% |
Microba Life seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Microba Life Sciences from analyzing the firm fundamentals such as Profit Margin of (1.65) %, current valuation of 61.31 M, and Return On Equity of -0.5 as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.9559 | Enterprise Value 61.3 M | Enterprise Value Ebitda (8.00) | Price Sales 6.6677 | Enterprise Value Revenue 5.0707 |
Overvalued
Today
Please note that Microba Life's price fluctuation is out of control at this time. Calculation of the real value of Microba Life Sciences is based on 3 months time horizon. Increasing Microba Life's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Microba Life's intrinsic value may or may not be the same as its current market price of 0.19, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.19 | Real 0.15 | Hype 0.19 |
The intrinsic value of Microba Life's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Microba Life's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Microba Life Sciences helps investors to forecast how Microba stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Microba Life more accurately as focusing exclusively on Microba Life's fundamentals will not take into account other important factors: Microba Life Cash |
|
Microba Life Total Value Analysis
Microba Life Sciences is now projected to have takeover price of 61.31 M with market capitalization of 80.61 M, debt of 1.58 M, and cash on hands of 12.43 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Microba Life fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
61.31 M | 80.61 M | 1.58 M | 12.43 M |
Microba Life Investor Information
About 55.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.96. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Microba Life Sciences recorded a loss per share of 0.05. The entity had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Microba Life's historical financial statements, Microba Life Sciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Microba Life Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Microba Life has an asset utilization ratio of 20.83 percent. This implies that the Company is making USD0.21 for each dollar of assets. An increasing asset utilization means that Microba Life Sciences is more efficient with each dollar of assets it utilizes for everyday operations.Microba Life Ownership Allocation
Microba Life Sciences maintains a total of 447.85 Million outstanding shares. Microba Life Sciences holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Microba Life Profitability Analysis
The company reported the revenue of 12.09 M. Net Loss for the year was (19.94 M) with profit before overhead, payroll, taxes, and interest of 2.68 M.About Microba Life Valuation
The stock valuation mechanism determines Microba Life's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Microba Life Sciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Microba Life. We calculate exposure to Microba Life's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Microba Life's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -8.6 M | -8.2 M |
Additional Tools for Microba Stock Analysis
When running Microba Life's price analysis, check to measure Microba Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microba Life is operating at the current time. Most of Microba Life's value examination focuses on studying past and present price action to predict the probability of Microba Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microba Life's price. Additionally, you may evaluate how the addition of Microba Life to your portfolios can decrease your overall portfolio volatility.